Hostname: page-component-cd9895bd7-dzt6s Total loading time: 0 Render date: 2024-12-26T07:47:01.915Z Has data issue: false hasContentIssue false
  • English
  • Français

Can genital-tract human papillomavirus infection and cervical cancer be prevented with a vaccine?

Published online by Cambridge University Press:  19 April 2004

Joakim Dillner  and
Darron R. Brown
Joakim Dillner
Affiliation:
Division of Laboratory Medicine, Department of Medical Microbiology, University Hospital at Malmö, Lund University, S-20502 Malmö, Sweden.
Darron R. Brown
Affiliation:
Department of Medicine, and Department of Microbiology and Immunology, Indiana University School of Medicine, 545 Barnhill Drive, Indianapolis, IN 46202, USA.
Get access Rights & Permissions [Opens in a new window]

Abstract

Human papillomavirus (HPV) infection is the cause of squamous cell carcinoma of the uterine cervix. This causative relationship has provided the rationale and incentive for development of a prophylactic vaccine. Such a vaccine, if found to be effective, could reduce the need for cervical cancer screening and have a profound effect on the incidence of cervical and other anogenital cancers. This review begins by examining the basic biological and epidemiological principles relevant to the development of HPV preventative vaccines. It then summarises studies examining the use of vaccines to prevent HPV infection in animals and humans, and, finally, discusses some of the unanswered issues surrounding vaccine development against HPV infection and cervical cancer.

Keywords

HPVhuman papillomaviruscervical cancervaccine
Type
Review Article
Information
Expert Reviews in Molecular Medicine , Volume 6 , Issue 9 , 20 April 2004 , pp. 1 - 21
Copyright
© Cambridge University Press 2004

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)